It seems that billionaire biotech investor Jim Mellon is the flavor of the month as he continues the drive to create a rejuvenation biotech industry. Jim and his colleagues at Juvenescence have announced that they have secured another $100M for the company, and it will be used to invest and support the growth of promising biotech companies working in this field.

Juvenescence has a varied investment portfolio of companies that range in potential usefulness, depending on your point of view, and they mostly favor the more traditional small molecule drug approach. There are a few companies that are of particular interest.